L. Michael Glodé, MD, of the University of Colorado Cancer Center, discusses study findings on adjuvant androgen deprivation vs mitoxantrone plus prednisone plus ADT in high-risk prostate cancer patients following radical prostatectomy. (Abstract 2)
Sumanta K. Pal, MD, of the City of Hope, discusses the evolution of circulating tumor DNA profile from first-line to second-line therapy in metastatic renal cell carcinoma. (Abstract 434)
Roland Seiler, MD, of the University of British Columbia, discusses in German a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based neoadjuvant chemotherapy, and which patients show the most benefit. (Abstract 281)
W. Marston Linehan, MD, of the National Cancer Institute, discusses the genetic basis of the different types of kidney cancer, which provides the key to clinical management.
Charles G. Drake, MD, PhD, of Columbia University Medical Center, summarizes his keynote lecture on immunotherapy as a new frontier in prostate cancer and its synergistic use with traditional treatments.
Rana R. McKay, MD, of the University of California, San Diego, discusses study findings on PD-1/PD-L1 responders with metastatic renal cell carcinoma who discontinue therapy for immune-related adverse events. (Abstract 467)
